Germline and somatic genetic variability of oxysterol-related genes in breast cancer patients with early disease of the luminal subtype.


Journal

Biochimie
ISSN: 1638-6183
Titre abrégé: Biochimie
Pays: France
ID NLM: 1264604

Informations de publication

Date de publication:
Aug 2022
Historique:
received: 07 03 2022
revised: 12 04 2022
accepted: 29 04 2022
pubmed: 8 5 2022
medline: 16 6 2022
entrez: 7 5 2022
Statut: ppublish

Résumé

Oxysterols, oxidized derivatives of cholesterol, have been implicated in multiple pathologies, including cancer. In breast cancer, the link is especially strong due to interactions between oxysterols and estrogen receptor activity. Here, we provide the first dedicated study of 113 oxysterol-related genes in breast cancer patients of the luminal subtype, in terms of both their somatic and germline variability, using targeted high-throughput DNA sequencing of 100 normal-tumor pairs with very high coverage. In the full cohort, or subsets of patients stratified by therapy, we found 12 germline variants in ABCA1, ABCA8, ABCC1, GPR183, LDLR, MBTPS1, NR1I2, OSBPL2, OSBPL3, and OSBPL5 to associate with poor survival of patients and variants in ABCA8, ABCG2, and HSD3B7 (three in total) associated with better survival. However, no associations remained significant after correction for multiple tests. Analysis of somatic variants revealed significantly (after FDR correction) poorer survival in patients mutated in CYP46A1 and 9 interacting (according to STRING analysis) genes, as well as in OSBPL3 and a set of 20 genes that collectively associated with the progesterone receptor status of patients. We propose further exploration of these genes in an integrative manner together with gene expression and epigenomic data.

Identifiants

pubmed: 35525372
pii: S0300-9084(22)00110-9
doi: 10.1016/j.biochi.2022.04.015
pii:
doi:

Substances chimiques

OSBPL2 protein, human 0
Oxysterols 0
Receptors, Steroid 0

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

158-169

Informations de copyright

Copyright © 2022 Elsevier B.V. and Société Française de Biochimie et Biologie Moléculaire (SFBBM). All rights reserved.

Déclaration de conflit d'intérêts

Declaration of competing interest Declarations of interest: none.

Auteurs

Petr Holý (P)

Toxicogenomics Unit, National Institute of Public Health, Prague, Czech Republic; Third Faculty of Medicine, Charles University, Prague, Czech Republic; Biomedical Center, Faculty of Medicine in Pilsen, Charles University, Pilsen, Czech Republic.

Viktor Hlaváč (V)

Toxicogenomics Unit, National Institute of Public Health, Prague, Czech Republic; Biomedical Center, Faculty of Medicine in Pilsen, Charles University, Pilsen, Czech Republic.

Pavel Ostašov (P)

Biomedical Center, Faculty of Medicine in Pilsen, Charles University, Pilsen, Czech Republic.

Veronika Brynychová (V)

Toxicogenomics Unit, National Institute of Public Health, Prague, Czech Republic; Biomedical Center, Faculty of Medicine in Pilsen, Charles University, Pilsen, Czech Republic.

Renata Koževnikovová (R)

Department of Oncosurgery, MEDICON, Prague, Czech Republic.

Markéta Trnková (M)

Aeskulab, k.s., Prague, Czech Republic.

Kateřina Kopečková (K)

Department of Oncology, Second Faculty of Medicine, Charles University and Motol University Hospital, Prague, Czech Republic.

Soňa Měšťáková (S)

Department of Surgery, Second Faculty of Medicine, Charles University and Motol University Hospital, Prague, Czech Republic.

Marcela Mrhalová (M)

Department of Pathology, Second Faculty of Medicine, Charles University and Motol University Hospital, Prague, Czech Republic.

Pavel Souček (P)

Toxicogenomics Unit, National Institute of Public Health, Prague, Czech Republic; Biomedical Center, Faculty of Medicine in Pilsen, Charles University, Pilsen, Czech Republic. Electronic address: pavel.soucek@szu.cz.

Articles similaires

Genome, Chloroplast Phylogeny Genetic Markers Base Composition High-Throughput Nucleotide Sequencing

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C

Classifications MeSH